In CCA, the combination of PI3K/AKT pathway inhibitors with MAPK pathway-targeting drugs has demonstrated synergistic effects, enhancing the total response and postponing the development of resistant clones [51,114,117]. Here, AKT1 is linked to cholangiocarcinoma.